Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New developments in immunosuppressive therapy].

U T Hopt1

  • 1Chirurgische Universitätsklinik Freiburg, Hugstetterstrasse 55, 79106 Freiburg.

Kongressband. Deutsche Gesellschaft Fur Chirurgie. Kongress
|February 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical course and pancreas parenchyma sparing surgical treatment of severe pancreatic trauma.

Injury·2020
Same author

Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.

BMC cancer·2019
Same author

Management and outcomes of intraductal papillary mucinous neoplasms.

BJS open·2019
Same author

The rate of postoperative pancreatic fistula after distal pancreatectomy is independent of the pancreatic stump closure technique - A retrospective analysis of 284 cases.

Asian journal of surgery·2019
Same author

[Intrahepatic cholangiocarcinoma : Results after 84 resections].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2018
Same author

Pancreatitis After Pancreatoduodenectomy Predicts Clinically Relevant Postoperative Pancreatic Fistula.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2016
Same journal

[120th Congress of the German Surgical Society. 29 April-2 May 2003, Munich, Germany. Abstracts].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2004
Same journal

[Quality and economy--contradictory demands].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same journal

[Attractive work schedules--the Sinsheim model].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same journal

[Women research personnel also in advanced positions and how do women promote women in this manner?].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same journal

[Is surgery a male specialty?--Discussion of bias].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
Same journal

[Integrated clinical guidelines].

Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress·2003
See all related articles

Reliable drug monitoring is key for effective immunosuppression with minimal side effects. Tailoring immunosuppressive therapy, including monitoring neoral C2 levels and tacrolimus trough levels, is crucial for organ transplant success.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation

Context:

  • Optimizing immunosuppressive therapy is critical for organ transplant recipients.
  • Drug monitoring strategies vary significantly between different immunosuppressants.
  • Individualizing therapy based on organ type and patient risk is essential.

Purpose:

  • To review current strategies for drug monitoring in immunosuppressive therapy.
  • To highlight the importance of organ-specific immunosuppression.
  • To discuss the role of novel agents like sirolimus and IL-2 receptor antibodies.

Summary:

  • Effective immunosuppression requires reliable drug monitoring; C2 level monitoring for neoral and trough level monitoring for tacrolimus are sufficient.
  • Immunosuppressive therapy should be tailored to the specific organ transplant due to differing immunogenicity.

Related Experiment Videos

  • Sirolimus is effective in high-risk patients, can substitute for calcineurin antagonists, and IL-2 receptor antibodies offer a low-side-effect induction therapy.

    • Impact:

    • Improved patient outcomes through optimized immunosuppression and reduced side effects.
    • Guidance for clinicians on selecting appropriate drug monitoring and therapeutic strategies.
    • Advancement of immunosuppressive protocols in organ transplantation.